Product Details
Synonyms
GDF-2, GDF2, BMP-9, BMP9
Source
Human GDF-2, Tag Free (GD2-H5211) is expressed from human 293 cells (HEK293). It contains AA Ser 320 - Arg 429 (Accession # Q9UK05-1).
Predicted N-terminus: Ser 320
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries no "tag".
The protein has a calculated MW of 12.1 kDa. The protein migrates as 13 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in ACN, TFA in Water with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE

Human GDF-2, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA

Immobilized Human GDF-2, Tag Free (Cat. No. GD2-H5211) at 1 μg/mL (100 μL/well) can bind Human ALK-1, His Tag with a linear range of 20-156 ng/mL (QC tested).
Protocol
User Reviews Publish Comment

Background Introduction
Frontier Progress
- English Name:
Growth/differentiation factor 2
- Category:
- Listed Drugs Count:
0 Details
- Clinical Drugs Count:
1 Details
- Highest R&D Stage:
Phase 2 Clinical



















